GLMD
vs
S&P 500
GLMD
S&P 500
Over the past 12 months, GLMD has underperformed S&P 500, delivering a return of -78% compared to the S&P 500's +14% growth.
Stocks Performance
GLMD vs S&P 500
Performance Gap
GLMD vs S&P 500
Performance By Year
GLMD vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Galmed Pharmaceuticals Ltd
Glance View
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).